检索结果-南通市图书馆

γδT cells:origin and fate,subsets,diseases and immunotherapy

Signal Transduction and Targeted Therapy 2023年第12期8卷 5769-5806页

作者： Yi Hu Qinglin Hu Yongsheng Li ligong lu Zheng Xiang Zhinan Yin Dieter Kabelitz Yangzhe Wu Microbiology and Immunology Department School of MedicineFaculty of Medical ScienceJinan UniversityGuangzhouGuangdong 510632China Guangdong Provincial Key Laboratory of Tumour Interventional Diagnosis and Treatment Zhuhai Institute of Translational MedicineZhuhai People’s Hospital Affiliated with Jinan UniversityJinan UniversityZhuhaiGuangdong 519000China Department of Medical Oncology Chongqing University Cancer HospitalChongqing 400030China Biomedical Translational Research Institute Jinan UniversityGuangzhouGuangdong 510632China Institute of Immunology Christian-Albrechts-University KielKielGermany

The intricacy of diseases,shaped by intrinsic processes like immune system exhaustion and hyperactivation,highlights the potential of immune renormalization as a promising strategy in disease treatment.In recent years,our primary focus has centered onγδT cell-based immunotherapy,particularly pioneering the use of allogeneic Vδ2+γδT cells for treating late-stage solid tumors and tuberculosis patients.However,we recognize untapped potential and optimization opportunities to fully harnessγδT cell effector functions in immunotherapy.This review aims to thoroughly examineγδT cell immunology and its role in diseases.Initially,we elucidate functional differences betweenγδT cells and theirαβT cell counterparts.We also provide an overview of major milestones inγδT cell research since their discovery in 1984.Furthermore,we delve into the intricate biological processes governing their origin,development,fate decisions,and T cell receptor(TCR)rearrangement within the thymus.By examining the mechanisms underlying the anti-tumor functions of distinctγδT cell subtypes based onγδTCR structure or cytokine release,we emphasize the importance of accurate subtyping in understandingγδT cell function.We also explore the microenvironment-dependent functions ofγδT cell subsets,particularly in infectious diseases,autoimmune conditions,hematological malignancies,and solid tumors.Finally,we propose future strategies for utilizing allogeneicγδT cells in tumor immunotherapy.Through this comprehensive review,we aim to provide readers with a holistic understanding of the molecular fundamentals and translational research frontiers ofγδT cells,ultimately contributing to further advancements in harnessing the therapeutic potential ofγδT cells.

关键词： γδT immunotherapy diseases

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

引用

Signal Transduction and Targeted Therapy 2022年第8期7卷 2707-2709页

作者： Gen Li Zhongcheng Zhou Peng Du Meixiao Zhan Ning Li Xinxin Xiong Shengjun Tang Miao Man Daniel T.Baptista-Hon ligong lu Guangzhou Women and Children’s Medical Center Guangzhou Medical UniversityGuangzhouChina Zhuhai Precision Medicine Center Zhuhai People’s HospitalThe First Affiliated Hospital of Faculty of MedicineMacao University of TechnologyZhuhaiGuangdongChina Department of Bioinformatics and AI Guangzhou LaboratoryGuangzhouChina University Hospital and Center for Biomedicine and Innovations Faculty of MedicineMacao University of Science and TechnologyTaipa 999078 MacaoChina Present address:University Hospital and Center for Biomedicine and Innovations Faculty of MedicineMacao University of Science and TechnologyTaipa 999078 MacaoChina

Dear Editor,Emerging epidemiology data indicate that the Omicron BA.2 sublineage is expected to become the dominant strain owing to its enhanced transmissibility.1 The BA.1 sublineage reduced the efficacy of neutralizing antibodies.2,3 The BA.2 sublineage may possess similar neutralizing antibody evasion.3 However,booster(3rd dose)vaccination strategies,or three exposures to the SARS-CoV2 spike protein through natural infection elicits strong neutralizing antibody responses.This raises the question of whether booster doses also elicit neutralizing antibody responses against BA.2.We present in this study the neutralization activity of serum from human recipients of homologous booster(three doses of CoronaVac inactivated vaccine)or heterologous booster(inactivated vaccine priming dose with BnT162b2 third dose)vaccine regimens against pseudovirus containing the Omicron BA.2 spike protein.We also evaluated the neutralizing activities of 6 monoclonal antibodies,and serum from monkeys vaccinated with a recombinant RBD protein vaccine.Finally,we also evaluated cell entry mediated by the Omicron BA.2 spike protein.

关键词： vaccine doses epidemiology

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

m^(6)A mRNA modification potentiates Th17 functions to inflame autoimmunity

引用

Science China(Life Sciences) 2023年第11期66卷 2543-2552页

作者： Xuefei Wang Chen Chen Hongwei Sun Kaiqiong Mao Jiameng Yao Weiqiao Zhang Meixiao Zhan Hua-Bing Li Zhiren Zhang Shu Zhu ligong lu Department of Geriatrics Medical Center on Aging of Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Shanghai Institute of Immunology State Key Laboratory of Oncogenes and Related GenesShanghai Jiao Tong University School of MedicineShanghai 200025China Institute of Immunology The CAS Key Laboratory of Innate Immunity and Chronic DiseaseDivision of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230001China Institute of Health and Medicine Hefei Comprehensive National Science CenterHefei 230601China Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment Zhuhai Interventional Medical CenterZhuhai People’s Hospital(Zhuhai Hospital Affiliated with Jinan University)Zhuhai 519000China

N6-methyladenosine(m^(6)A),the most common and abundant epigenetic RNA modification,governs mRNA metabolism to determine cell differentiation,proliferation and response to stimulation.m^(6)A methyltransferase METTL3 has been reported to control T cell homeostasis and sustain the suppressive function of regulatory T cells(Tregs).However,the role of m^(6)A methyltransferase in other subtypes of T cells remains unknown.T helper cells 17(Th17)play a pivotal role in host defense and autoimmunity.Here,we found that the loss of METTL3 in T cells caused serious defect of Th17 cell differentiation,and impeded the development of experimental autoimmune encephalomyelitis(EAE).We generated Mettl3f/fIl17aCre mice and observed that METTL3 deficiency in Th17 cells significantly suppressed the development of EAE and displayed less Th17 cell infiltration into central nervous system(CNS).Importantly,we demonstrated that depletion of METTL3 attenuated IL-17A and CCR5 expression by facilitating SOCS3 mRNA stability in Th17 cells,leading to disrupted Th17 cell differentiation and infiltration,and eventually attenuating the process of EAE.Collectively,our results highlight that m^(6)A modification sustains Th17 cell function,which provides new insights into the regulatory network of Th17 cells,and also implies a potential therapeutic target for Th17 cell mediated autoimmune disease.

关键词： m^(6)A modification Th17 cells EAE SOCS family

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Hypoxia-degradable and long-circulating zwitterionic phosphorylcholine-based nanogel for enhanced tumor drug delivery

引用

Acta Pharmaceutica Sinica B 2021年第2期11卷 560-571页

作者： Shaojun Peng Boshu Ouyang Yongjie Xin Wei Zhao Shun Shen Meixiao Zhan ligong lu Zhuhai Precision Medical Center Zhuhai Interventional Medical CenterZhuhai People’s Hospital(Zhuhai Hospital Affiliated with Jinan University)Zhuhai 519000China The Institute for Translational Nanomedicine Shanghai East HospitalTongji University School of MedicineShanghai 200120China Zhejiang Cancer Hospital Institute of Cancer ResearchHangzhou 310012China Central Laboratory First Affiliated HospitalInstitute(College)of Integrative MedicineDalian Medical UniversityDalian 116021China

Tumor microenvironment has been widely utilized for advanced drug delivery in recent years,among which hypoxia-responsive drug delivery systems have become the research hotspot.Although hypoxia-responsive micelles or polymersomes have been successfully developed,a type of hypoxia-degradable nanogel has rarely been reported and the advantages of hypoxia-degradable nanogel over other kinds of degradable nanogels in tumor drug delivery remain unclear.Herein,we reported the synthesis of a novel hypoxia-responsive crosslinker and the fabrication of a hypoxia-degradable zwitterionic poly(phosphorylcholine)-based(HPMPC)nanogel for tumor drug delivery.The obtained HPMPC nanogel showed ultra-long blood circulation and desirable immune compatibility,which leads to high and long-lasting accumulation in tumor tissue.Furthermore,HPMPC nanogel could rapidly degrade into oligomers of low molecule weight owing to the degradation of azo bond in hypoxic environment,which leads to the effective release of the loaded drug.Impressively,HPMPC nanogel showed superior tumor inhibition effect both in vitro and in vivo compared to the reduction-responsive phosphorylcholine-based nanogel,owing to the more complete drug release.Overall,the drug-loaded HPMPC nanogel exhibits a pronounced tumor inhibition effect in a humanized subcutaneous liver cancer model with negligible side effects,which showed great potential as nanocarrier for advanced tumor drug delivery.

关键词： Hypoxia-degradable Zwitterionic nanogel Long blood circulation Drug release Drug delivery

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

mA mRNA modification potentiates Th17 functions to inflame autoimmunity

引用

Science China Life Sciences 2023年

作者： Xuefei Wang Chen Chen Hongwei Sun Kaiqiong Mao Jiameng Yao Weiqiao Zhang Meixiao Zhan Huabing Li Zhiren Zhang Shu Zhu ligong lu Institute of Immunology The CAS Key Laboratory of Innate Immunity and Chronic Disease Division of Life Sciences and MedicineUniversity of Science and Technology of China Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment Zhuhai Interventional Medical Center Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University) Institute of Health and Medicine Hefei Comprehensive National Science Center Shanghai Institute of Immunology State Key Laboratory of Oncogenes and Related Genes Shanghai Jiao Tong University School of Medicine Department of Geriatrics Medical Center on Aging of Ruijin Hospital Shanghai Jiao Tong University School of Medicine

N6-methyladenosine(m6A), the most common and abundant epigenetic RNA modification, governs mRNA metabolism to determine cell differentiation, proliferation and response to stimulation. m6A methyltransferase METTL3 has been reported to control T cell homeostasis and sustain the suppressive function of regulatory T cells(Tregs). However, the role of m6A methyltransferase in other subtypes of T cells remains unknown. T helper cells 17(Th17) play a pivotal role in host defense and autoimmunity. Here, we found that the loss of METTL3 in Tcells caused serious defect of Th17 cell differentiation, and impeded the development of experimental autoimmune encephalomyelitis(EAE). We generated Mettl3f/fIl17aCremice and observed that METTL3 deficiency in Th17 cells significantly suppressed the development of EAE and displayed less Th17 cell infiltration into central nervous system(CNS). Importantly, we demonstrated that depletion of METTL3 attenuated IL-17A and CCR5 expression by facilitating SOCS3 mRNA stability in Th17 cells, leading to disrupted Th17 cell differentiation and infiltration, and eventually attenuating the process of EAE. Collectively, our results highlight that m6A modification sustains Th17 cell function,which provides new insights into the regulatory network of Th17 cells, and also implies a potential therapeutic target for Th17cell mediated autoimmune disease.

关键词：

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Photosensitizer conjugate-functionalized poly(hexamethylene guanidine) for potentiated broad-spectrum bacterial inhibition and enhanced biocompatibility

引用

Chinese Chemical Letters 2020年第9期31卷 2516-2519页

作者： Fengfeng Xiao Bing Cao Liewei Wen Yanhong Su Meixiao Zhan ligong lu Xianglong Hu MOE Key Laboratory of Laser Life Science&Institute of Laser Life Science College of BiophotonicsSouth China Normal UniversityGuangzhou 510631China Guangdong Provincial Key Laboratory of Laser Life Science College of BiophotonicsSouth China Normal UniversityGuangzhou 510631China Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityJinanUniversityZhuhai 519000China

Pathogen infection is the main cause of human morbidity and death.Traditional antibiotics usually sterilize bacteria in chemical ways,which tends to develop serious antibiotic resistance.Cationic polymers exhibit good bacterial inhibition with less resistance,but often face severe cytotoxicity toward normal cells.The optimization of polymeric antimicrobials for enhanced bactericidal capacity and improved biocompatibility is quite meaningful.In addition,photodynamic therapy(PDT) is a therapeutic modality with less susceptibility to develop resistance.Herein,a typical commercial polymeric antimicrobial,polyhexamethylene guanidine(PHMG) was selected for current proof-of-concept optimization due to its excellent bactericidal capacity but moderate biocompatibility.Eosin-Y(EoS)was copolymerized to afford EoS-labeled polymer conjugates,poly(2-(dimethylamino) ethyl methacrylate-co-eosin),P(DMAEMA-co-EoS),which was conjugated with PHMG to afford a novel polymeric antimicrobial,P(DMAEMA-co-EoS)-b-PHMG-b-P(DMAEMA-co-EoS),noted as PEoS-PHMG.It could efficiently kill broad-spectrum bacteria by physical damage and photodynamic therapy.Compared with PHMG,the bacterial inhibition of PEoS-PHMG was potentiated after the functionalization.Furthermore,PEoS-PHMG exhibited low cytotoxicity and minimal hemolysis,which was demonstrated by cell viability assays toward LO2 cells and RAW 264.7 cells as well as hemolytic assays against red blood cells.These results confirmed that the resultant PEoS-PHMG could act as promising alternative antibacterial materials with excellent broad-spectrum bacterial inhibition and favorable biocompatibility.

关键词： Poly(hexamethylene guanidine) Photodynamic therapy Eosin-Y Broad-spectrum bacterial Inhibition Biocompatibility

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

引用

Science China(Life Sciences) 2020年第12期63卷 1833-1849页

作者： ligong lu Hui Zhang Meixiao Zhan Jun Jiang Hua Yin Danielle JDauphars Shi-You Li Yong Li You-Wen He Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityZhuhai 519000China First Affiliated Hospital China Medical UniversityShenyang 110001China tricision Biotherapeutic Inc. Zhuhai 519041China Department of Immunology Duke University Medical University Medical CenterDurhamNC 27710USA

The newly emerged severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019(COVID-19) due to SARSCoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARSCoV-2 infection is a critical determinant for patients’ outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

关键词： COVID-19 seroconversion neutralizing antibody spike protein SARS-CoV-2 convalescent plasma vaccine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy

引用

Nano Research 2021年第11期14卷 3913-3920页

作者： Wei Jiang Han Zhou Qin Wang Ziqi Chen Wang Dong Zixuan Guo Yong Li Wei Zhao Meixiao Zhan Yucai Wang ligong lu Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People’s Hospital(Zhuhai Hospital Affiliated with Jinan University)Zhuhai519000China Division of Molecular Medicine Hefei National Laboratory for Physical Sciences at Microscalethe CAS Key Laboratory of Innate Immunity and Chronic DiseaseSchool of Life SciencesUniversity of Science and Technology of ChinaHefei230026China

Tumor cells undergoing immunogenic cell death (ICD) have emerged as an in situ therapeutic vaccine helping to activate a persistent anti-tumor response. Several chemotherapeutic agents have been demonstrated to induce ICD, however accompanied with severe adverse effects in the clinic, weakening its immune responses. Herein, to elicit an intensive ICD while minimizing the systemic toxicity, we introduce a tumor targeting peptide modified bortezomib (BTZ) loading nanomedicine (i-NPBTZ) for the efficient delivery and controlled release of BTZ in tumors. This system is constructed by conjugating BTZ to PEGylated polyphenols via a pH-sensitive covalent boronate-phenol bond that allows them to self-assemble into nanovesicles in neutral condition with high drug loading efficiency. Once accumulated in acidic environment, BTZ-phenolic network is disassembled and thereby accelerates the release of BTZ from nanocarriers. The released BTZ selectively kill tumor cells with a concomitant evocation of tumor-specific cytotoxic T cells by triggering ICD in vivo. This can finally lead to an extended tumor ablation and prevention of distant metastasis in a syngeneic tumor mouse model, while reducing the systemic toxicity of BTZ. In general, our system offers a novel concept with clinical potential to exploit ICD for potentiating tumor immunotherapy and also provides an excellent example of the application of polymer-drug interaction for efficient drug delivery and controllable release.

关键词： bortezomib boronate-phenolic network pH-responsiveness immunogenic cell death cancer immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China

引用

Acta Pharmaceutica Sinica B 2021年第6期11卷 1526-1540页

作者： Zhiqiang Wang Zhibo Zhang Yong Li Li Sun Dezhen Peng Danyu Du Xian Zhang luwei Han Liwen Zhao ligong lu Hongzhi Du Shengtao Yuan Meixiao Zhan Jiangsu Key Laboratory of Drug Screening China Pharmaceutical UniversityNanjing 210003China Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityJinan UniversityZhuhai 519000China Sanhome Pharmaceutical Co. Ltd.Nanjing 210000China School of Pharmacy Hubei University of Chinese MedicineWuhan 430065China

Acute myeloid leukaemia(AML) is the most common form of acute leukaemia in adults,with increasing incidence with age and a generally poor prognosis.Almost 20% of AML patients express mutant isocitrate dehydrogenase 2(mIDH2),which leads to the accumulation of the carcinogenic metabolite 2-hydroxyglutarate(2-HG),resulting in poor prognosis.Thus,global institutions have been working to develop mIDH2 inhibitors.SH1573 is a novel mIDH2 inhibitor that we independently designed and synthesised.We have conducted a comprehensive study on its pharmacodynamics,pharmacokinetics and safety.First,SH1573 exhibited a strong selective inhibition of mIDH2 R140 Q protein,which could effectively reduce the production of 2-HG in cell lines,serum and tumors of an animal model.It could also promote the differentiation of mutant AML cell lines and granulocytes in PDX models.Then,it was confirmed that SH1573 possessed characteristics of high bioavailability,good metabolic stability and wide tissue distribution.Finally,toxicological data showed that SH1573 had no effects on the respiratory system,cardiovascular system and nervous system,and was genetically safe.This research successfully promoted the approval of SH1573 for clinical trials(CTR20200247).All experiments demonstrated that,as a potential drug against mIDH2 R140 Q acute myeloid leukaemia,SH1573 was effective and safe.

关键词： Acute myeloid leukaemia Tumor metabolism Mutant isocitrate dehydrogenase 2(mIDH2) mIDH2 inhibitor SH1573 2-Hydroxyglutarate Differentiation Preclinical efficacy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

基于TACE联合治疗原发性肝细胞癌的研究进展

引用

介入放射学杂志 2024年第6期33卷 688-692页

作者：肖正芳郑游冰邓飞燕郑思茜孙宏伟刘妍妍陆骊工暨南大学附属珠海医院（珠海市人民医院）广东省肿瘤介入诊疗重点实验室

肝癌是常见且恶性程度高的癌症之一，其中90%为肝细胞癌，对人类健康构成严重威胁。由于早期肝癌无特异性表现，大部分确诊时已处于中晚期，错过了最佳的根治治疗时机。关于中晚期原发性肝细胞癌治疗的探索从未停歇。近年来，经动脉化... 详细信息

肝癌是常见且恶性程度高的癌症之一，其中90%为肝细胞癌，对人类健康构成严重威胁。由于早期肝癌无特异性表现，大部分确诊时已处于中晚期，错过了最佳的根治治疗时机。关于中晚期原发性肝细胞癌治疗的探索从未停歇。近年来，经动脉化疗栓塞术（transarterial chemoembolization,TACE）已被纳入原发性肝细胞癌的标准治疗方案中。随着多学科综合治疗的推进，各种减轻肝细胞癌负荷的治疗方案已经广泛应用于临床中，如肝动脉灌注化疗（hepatic artery infusion chemotherapy,HAIC）、靶向治疗和免疫治疗等与TACE的联用，提高了肝癌患者的总生存率。本文重点介绍原发性肝细胞癌研究中，TACE与其他疗法的联用在降低肿瘤负荷、提高患者生存率方面的进展，并总结联合治疗中需要进行更深入研究的关键问题。

关键词：肝细胞癌肝动脉化疗栓塞灌注化疗靶向治疗免疫治疗联合治疗

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：